It has demonstrated activity in-vivo and in-vitro preclinical, GIST models across a broad range of primary and secondary KIT/PDGFRA mutations that confer resistance to standard of care agents [35]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.